A Defense Reaction of Cancer Cells to Injury with Focus on Fibrinogen

Péter Hamar

DOI: https://doi.org/10.3390/ijms25063435

IF: 5.6

2024-03-20

International Journal of Molecular Sciences

Abstract:This review is intended to demonstrate that the local production of acute phase proteins (termed local acute phase response (lAPR)) and especially fibrin/fibrinogen (FN) is a defense mechanism of cancer cells to therapy, and inhibition of the lAPR can augment the effectiveness of cancer therapy. Previously we detected a lAPR accompanying tumor cell death during the treatment of triple-negative breast cancer (TNBC) with modulated electro-hyperthermia (mEHT) in mice. We observed a similar lAPR in in hypoxic mouse kidneys. In both models, production of FN chains was predominant among the locally produced acute phase proteins. The production and extracellular release of FN into the tumor microenvironment is a known method of self-defense in tumor cells. We propose that the lAPR is a new, novel cellular defense mechanism like the heat shock response (HSR). In this review, we demonstrate a potential synergism between FN inhibition and mEHT in cancer treatment, suggesting that the effectiveness of mEHT and chemotherapy can be enhanced by inhibiting the HSR and/or the lAPR. Non-anticoagulant inhibition of FN offers potential new therapeutic options for cancer treatment.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of local acute - phase response (lAPR), especially fibrinogen (FN), in the defense mechanisms of cancer cells against damage, and to study whether inhibiting lAPR can enhance the effectiveness of cancer treatment. Specifically, the authors found through research that when cancer cells are damaged by treatment (such as modulated electro - hyperthermia, mEHT), they will locally produce acute - phase proteins, especially fibrinogen, as a self - protection mechanism. This locally - produced acute - phase protein response is different from the traditional systemic acute - phase protein response, and it occurs locally in tissue damage or inflammation. The authors propose that by inhibiting this local acute - phase protein response, the effectiveness of cancer treatment can be improved, for example, by combining mEHT and chemotherapy.

The key points mentioned in the paper include:
- **Local acute - phase response (lAPR)**: This is a new cell defense mechanism, similar to the heat shock response (HSR), which is activated when cancer cells are damaged.
- **The role of fibrinogen (FN)**: FN is not only involved in blood coagulation, but also forms a protective structure in the tumor microenvironment, promoting the survival and metastasis of cancer cells.
- **Experimental model**: Use triple - negative breast cancer (TNBC) mouse models and modulated electro - hyperthermia (mEHT) to observe and analyze lAPR.
- **Experimental results**: Through multi - omics analysis techniques (such as next - generation sequencing NGS, NanoString, and mass spectrometry MS), it was confirmed that a large amount of acute - phase proteins, especially FN, were locally produced in tumor cells after mEHT treatment.
- **Potential treatment strategies**: Inhibiting the production of FN may help enhance the effects of mEHT and chemotherapy, thereby treating cancer more effectively.

In summary, this paper aims to reveal the potential role of local acute - phase protein response in cancer treatment and propose a new strategy to improve treatment effectiveness by inhibiting this response.